Paulo Nuciforo

49PUBLICATIONS
509CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersBiological adaptationInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (49)

|Oct 14, 2026
Talazoparib plus enzalutamide in high-volume metastatic hormone-naive prostate cancer: a randomized phase 2 trial.

|Jul 13, 2026
Application of a Translational Research Platform to Unveil Efficacy Signals and Mechanisms of Resistance of FGFR Inhibitors in Multiple FGFR-Altered Solid Tumors.

|Jun 08, 2026
Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy.

|Apr 04, 2026
Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.

Jaume Capdevila, Jorge Hernando, Javier Molina-Cerillo

|Dec 16, 2025
Broad Utility of Ultrasensitive Analysis of ctDNA Dynamics across Solid Tumors Treated with Immunotherapy.

Elena Garralda, Charles Abbott, Alma Calahorro

|Apr 08, 2025
Convergent Genetic Adaptation in Human Tumors Developed Under Systemic Hypoxia and in Populations Living at High Altitudes.

Carlota Arenillas, Lucía Celada, José Ruiz-Cantador

Pageof 9

Frequent Collaborators

17 joint publications

Josep Tabernero

10 joint publications

Mafalda Oliveira

9 joint publications

Cristina Saura

8 joint publications

Joaquín Arribas